JGC
AVDL

J. Goldman & Co’s Avadel Pharmaceuticals AVDL Stock Holding History

J. Goldman & Co’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-94,867
Closed -$1.45M – 570
2025
Q3 		$1.45M Sell
94,867
-168,496
-64% -$2.19M 0.04% 302
2025
Q2 		$2.33M Buy
263,363
+47,363
+22% +$416K 0.06% 260
2025
Q1 		$1.69M Buy
216,000
+175,653
+435% +$1.47M 0.04% 317
2024
Q4 		$424K Sell
40,347
-48,033
-54% -$583K 0.01% 371
2024
Q3 		$1.16M Sell
88,380
-86,572
-49% -$1.32M 0.03% 274
2024
Q2 		$2.46M Buy
+174,952
New +$2.85M 0.07% 229
2023
Q4 		– Sell
-163,382
Closed -$1.92M – 347
2023
Q3 		$1.68M Buy
163,382
+134,609
+468% +$1.8M 0.06% 214
2023
Q2 		$474K Sell
28,773
-152,227
-84% -$1.98M 0.02% 293
2023
Q1 		$1.66M Buy
181,000
+106,750
+144% +$878K 0.07% 217
2022
Q4 		$532K Buy
+74,250
New +$521K 0.03% 271
2021
Q1 		– Sell
-233,747
Closed -$1.56M – 435
2020
Q4 		$1.56M Sell
233,747
-174,878
-43% -$1.09M 0.08% 213
2020
Q3 		$2.06M Sell
408,625
-239,083
-37% -$1.74M 0.14% 166
2020
Q2 		$5.23M Buy
+647,708
New +$5.71M 0.32% 93
2018
Q1 		– Sell
-77,000
Closed -$631K – 340
2017
Q4 		$631K Sell
77,000
-314,839
-80% -$2.95M 0.03% 256
2017
Q3 		$4.11M Sell
391,839
-274,477
-41% -$2.62M 0.21% 132
2017
Q2 		$7.35M Sell
666,316
-330,684
-33% -$3.32M 0.4% 80
2017
Q1 		$9.65M Buy
+997,000
New +$9.97M 0.48% 60
2016
Q4 		– Sell
-823,000
Closed -$10.2M – 299
2016
Q3 		$10.2M Sell
823,000
-474,415
-37% -$6.2M 0.58% 46
2016
Q2 		$13.9M Buy
1,297,415
+179,415
+16% +$1.91M 0.73% 28
2016
Q1 		$12.3M Buy
1,118,000
+495,000
+79% +$4.92M 0.77% 30
2015
Q4 		$7.61M Buy
623,000
+210,120
+51% +$3.28M 0.78% 31
2015
Q3 		$6.73M Buy
412,880
+384,465
+1,353% +$8.47M 0.58% 56
2015
Q2 		$602K Buy
28,415
+3,415
+14% +$61.2K 0.04% 203
2015
Q1 		$450K Sell
25,000
-78,125
-76% -$1.22M 0.03% 252
2014
Q4 		$1.77M Buy
+103,125
New +$1.47M 0.21% 124

Other funds holding AVDL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

J. Goldman & Co's AVDL Position: Q4 2025 in Review

J. Goldman & Co sold out of Avadel Pharmaceuticals (AVDL) in Q4 2025, closing a stake of 94,867 shares — an estimated $1.45M sold.

J. Goldman & Co first reported a position in AVDL in Q4 2014 and held it in 25 quarters. The position peaked at $13.9M in Q2 2016. 207 funds tracked by Wall St. Rank hold AVDL as of Q4 2025.

  • J. Goldman & Co reported no remaining Avadel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • J. Goldman & Co sold 94,867 Avadel Pharmaceuticals shares in Q4 2025, an estimated $1.45M.
  • J. Goldman & Co first reported a position in Avadel Pharmaceuticals in Q4 2014 and held it in 25 quarters.
  • J. Goldman & Co's Avadel Pharmaceuticals position peaked at $13.9M in Q2 2016.
  • 207 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.